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Abstract: Surface-modified nanospheres can be utilized for
targeting drugs and diagnostic agents to the bone and bone
marrow while extending their circulation time in the blood
stream. The surface modification of poly(lactide-co-glycol-
ide) (PLGA) nanospheres by radioisotope carrying poly(eth-
ylene oxide)-poly (propylene oxide)-poly (ethylene oxide)
triblock copolymers (Poloxamer 407) has been assessed by in
vitro characterization and in vivo biodistribution studies after
intravenous administration of the nanospheres to the
mouse. A hydroxyphenylpropionic acid, a ligand for 125I
and 131I labeling, was conjugated to the hydroxyl group of
the Poloxamer 407 by using dicyclohexyl carbodiimide. The
ligand-conjugated Poloxamer 407 was adsorbed onto the
surface of PLGA nanospheres. Surface coating was con-
firmed by measuring both size distribution and the surface
charge of the nanospheres. Besides, 125I-labeling efficiency,
radiolabeling stability, whole body imaging, and biodistri-
bution of the radioisotope-labeled nanospheres were exam-
ined. Ligand-labeled, surface-modified PLGA nanospheres
were in 100-nm size ranges, which may be adequate for
long-circulation and further bone imaging. 125I-labeling ef-
ficiency was 90% and was more stable at human serum for
24 h. A noticeable decrease in liver or spleen uptake was
obtained by the surface-modified nanospheres. 125I-labeled
nanospheres showed higher blood maintenance and bone
uptake compared with stannous colloid with the same size
distribution. Therefore, a fully biodegradable, radioisotope-
carrying, surface-modified nanosphere system has been de-
veloped as a promising tool for targeting bone and bone
marrows. © 2003 Wiley Periodicals, Inc. J Biomed Mater Res
67A: 751–760, 2003
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INTRODUCTION
Bone and bone marrow imaging may be potentially
useful for prompt diagnosis of osteomyelitis, septic
arthritis, and multiple myeloma.1–5 As well as diag-
nosing bone disease, imaging bone marrow can be
useful for diagnosing cancer metastasis because it is a
favored site for metastasis of many solid tumors.6–10
Recent studies have shown that several intravenously
administered specific colloids can be taken up by bone
marrow, allowing the improved detection of small
bone tumors in an animal model.6–8 To this regard,
specific and high-resolution imaging of bone and bone
marrow can provide insight in determining the po-
tency of disease, and can help in planning the treat-
ment schedule. In addition, the success of imaging and
following therapy depends on the critical relationship
between the amount of radionuclides at the target
tissue and the normal tissue. Small particles in nano-
meter ranges have been routinely used in many clin-
ical diagnostic tests. As examples of bone and bone
marrow imaging agents, 99mTc-MDP,1,2 99mTc-anti-
mony colloid,1,2 99mTc-sulfur colloid,3,5 111Indium col-
loid,2 and 99mTc-labeled human serum albumin nano-
colloid4,5 are currently used. Generally, requirements
for a long-circulating bone imaging agent have been
high specificity to the bone, optimal blood stability of
radioisotope labeling, ability to avoid reticuloendothe-
lial system (RES) uptake by the liver or spleen, low
toxicity, and proper excretion.1–5,11–14
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Bone marrow targeting has been attempted by us-
ing the recognizable molecule, such as transferrin15–17;
however, targeting efficiency has been limited because
the transferrin receptor also exists in the liver and
spleen. The main hurdle for bone marrow targeting
and imaging, thus, is that it is difficult to find a specific
recognizable moiety by bone marrow surface endothe-
lial system, because the bone marrow surface primar-
ily has similar RES to liver or spleen except that bone
marrow has more fenestrated RES than liver or spleen.
A small fraction of the intravenously administered
particulates reaches the bone and bone marrow, the
next biggest RES than the liver and spleen, after re-
moval by the RES of the liver and spleen.18,19 How-
ever, because bone marrow has the biggest RES after
liver and spleen, passive direction after escaping liver/
spleen toward bone marrow has been the alternative to
ferry the diagnostics to the bone marrow.
To avoid rapid liver/spleen RES uptake and obtain
long circulation behavior, achieving proper particle
size between 50–150 nm with a hydrophilic surface
has been suggested.20,21 Unless the hydrophilic parti-
cles have the sugar moiety recognizable by hepato-
cytes in the liver, most nano-sized particles with hy-
drophilic polyethylene oxide (PEO) are considered to
extend retention time in the circulation. Indeed, coat-
ing colloidal particles with PEO has been able to
hinder the liver or spleen uptake and efficiently obtain
a deposition of the particles primarily in the bone
marrow.22,23 This effect is due to the steric repulsion of
the PEO chain against both protein adsorption and
particular macrophage adhesion by the liver or spleen.
Marked redirection toward the bone followed by bone
marrow uptake utilizing surface-modified particles
with the PEO chain, as well as prevention of the
liver/spleen uptake, has been demonstrated by sev-
eral previous reports.20–23 Several hypotheses related
to the interaction between PEO and bone marrow
macrophage, although it is not yet clear, have been
suggested to corroborate the improved bone uptake.
Herein, radioisotope-carrying, surface-modified poly-
(lactide-co-glycolide) (PLGA) nanospheres with poly-
(ethylene oxide)-poly(propylene oxide)-poly(ethylene
oxide) (PEO-PPO-PEO) triblock copolymer (Polox-
amer 407) were prepared for efficient targeted imag-
ing of the bone and bone marrow. Nanospheres were
made by routine o/w emulsion/evaporation method.
Poloxamer 407 coating was conducted by incubating
ligand-labeled poloxamer solution with prepared
nanospheres. Hydrophobic PPO unit can be anchored
into the surface of nanospheres whereas PEO unit may
increase the hydrophilicity of the surface of nano-
spheres. PEO units also induce repulsive steric hin-
drance, which interrupt the adhesion of the blood
protein and uptake by RES of liver or spleen. Before
incubation, PEO unit of the Poloxamer 407 was mod-
ified by ligand molecule that chelates radionuclide.
Hydroxyphenylpropionic acid (HPP), a ligand of ra-
dioactive 125I, 131I, was coupled to the hydroxyl group
of PEO by using a coupling agent, dicyclohexyl car-
bodiimide (DCC). Ligand-conjugated Poloxamer 407
was coated onto the nanoparticles, and specific radio-
nuclide to ligand, such as 125I or 131I, was labeled to
those surface-modified nanospheres before use in di-
agnosis. This unique method of labeling was expected
to overcome the limitation of the current labeling
method including physical entrapment into the nano-
sphere or direct coupling in respect to avoiding non-
specific leakage of isotope to the blood stream or loss
of radioactivity of isotope.24,25 These ligand-conju-
gated polymers are most favorable for being ready to
carry radioisotope in bone imaging. Radioisotopes
could be easily chelated with ligand-copolymer con-
jugates in a short time, which permits immediate use
for organ imaging and diagnosis. Also, the nanopar-
ticulate carrier may permit simultaneous encapsula-
tion of therapeutic drugs or gene vectors, thus provid-
ing a combined diagnostic and therapeutic bone/bone
marrow drug delivery system.
Conjugation of radioisotope-specific ligand to
Poloxamer 407, fabrication of nanospheres, surface
modification, and characterization of surface-coated
nanospheres, radioisotope labeling efficiency, stabil-
ity, and biodistribution of the nanospheres will be
discussed in this article.
MATERIALS AND METHODS
Materials
PLGA (MW 2000) was obtained from Polyscience Inc. (War-
rington, PA). 3-(4-Hydroxyphenyl) propionic acid (HPP) was
purchased from Aldrich Chemical Co. (Milwaukee, WI). DCC
was supplied from Sigma (St. Louis, MO). Poloxamer 407 was
obtained from BASF (Ladwingshafen, Germany). N-hydroxy-
succinimide was from Fluka (Ronkonkoma, NJ). Methylene
chloride and dimethylformamide (DMF) were purchased from
Yakuri Pure Chemicals Co. (Osaka, Japan). Polyvinyl alcohol
(PVA) was from Hayashi Pure Chemicals Ind. Ltd. (Osaka,
Japan). 125I and 131I were obtained from Amersham Co. (Buck-
inghamshire, UK). All other chemicals were of analytical grade.
Ligand conjugation with Poloxamer 407
Fifty milligrams of HPP, as a ligand for iodine, was dis-
solved in 30 mL of dried DMF containing 30 mg of DCC and
30 mg of N-hydroxysuccinimide. This mixture was stirred
for 2 h to activate carboxylic acid of HPP. Precipitants were
removed by centrifugation. Then Poloxamer 407, dissolved
in DMF, was added, and stirred for a further 4 h at room
temperature. The product was precipitated in an excess of
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dry ether. Then the precipitate was dissolved in 20 mL of
distilled water, dialyzed against distilled water (MWCO
1000), and freeze-dried. Formation of ligand-conjugated
Poloxamer 407 was ascertained by using Fourier transform
infrared spectrophotometer and differential scanning calo-
rimetry.
Nanosphere fabrication and surface modification
of PLGA nanospheres by HPP–Poloxamer 407
PLGA nanospheres were produced by an o/w emulsifi-
cation/solvent evaporation technique involving dropwise
addition of 30 mL of a solution of PLGA in methylene
chloride to 300 mL of an aqueous, 1.5% (w/v) solution of the
PVA stabilizer. The concentration of the PLGA solution was
2%. The PLGA solution was added over 1 min to the PVA
aqueous solution, which was stirred at a rate of 8000 rpm
using a Silverson homogenizer (Silverson Machines,
Chesham, UK), and stirring was continued for a further 10
min. These emulsions were heated at 85°C for 5 min and
further stirred to remove methylene chloride. The resulting
nanospheres were harvested and cleaned by repeated cen-
trifuging and suspending in distilled water three times, then
finally collected by lyophilization. The prepared nano-
spheres were further modified on their surface by incubat-
ing with HPP–Poloxamer 407 solution (5 mg/mL) for up to
24 h. HPP–Poloxamer 407 adsorbed nanospheres were col-
lected by spinning down the nanospheres by centrifugation
then freeze-drying. Surface coating by HPP–Poloxamer was
confirmed by measuring the size and surface zeta potential
of the nanospheres in accordance with incubation time.
Nanosphere particle size distribution and surface
potential
Zeta potential and particle size of the nanospheres were
measured according to the procedures reported elsewhere.
Briefly, solutions containing the above prepared nano-
spheres were placed into the cuvettes, and their surface
charge and particle size determined by measuring electro-
phoretic mobility using a NICOMP particle and zeta sizer
(NICOMP™ 380ELS, Santa Barbara, CA). All experiments
were performed at 25°C, pH 7.0 and 677 nm in wavelength,
and a constant angle of 15°. The zeta potential was automat-
ically calculated from the electrophoretic mobility based on
Smoluchowski’s formula. After determination of the electro-
phoretic mobility, samples were subject to measurements of
the mean particle size using the same equipment, light
source, and detection of wavelength. The particle size was
reported as the effective mean diameter.
Radioisotope labeling to surface-modified PLGA
nanospheres
125I was labeled to the surface-modified nanospheres us-
ing a modified Chloramine-T method.26 Bolton-Huntner
agent containing 125I was added to the activated HPP–Polox-
amer-coated nanosphere suspension. The labeling efficiency
and the radiochemical purity of labeled nanospheres were
checked by instant thin-layer chromatography/silica gel
(ITLC/SG) according to the manufacturer’s instruction. In
brief, radioisotope labeling to the nanospheres was detected
below the 40-mm line and unlabeled free radioisotopes were
detected above the 50-mm line. Labeling efficiency was pre-
sented as the ratio of the radioactivity read below 40 mm to
the total radioactivity. To examine the labeling stability of
the HPP–Poloxamer 407-coated nanospheres, radioisotope-
labeled nanospheres were incubated in human serum for
24 h at 37°C and then radioactivity of pure radioisotope-
labeled nanospheres was measured using the same method
described above.
Whole body imaging with surface-modified PLGA
nanospheres
Whole body imaging studies were performed using ICR
mice weighing 20–25 g and 4–7 weeks old. Mice were im-
aged at 5-min intervals for an hour after injection of 50 Ci
of 131I-labeled, HPP–Poloxamer-coated nanosphere suspen-
sion into the tail vein. Images were compared with that of
99mTc-labeled tin (Stannous) colloid. All animals were anes-
thetized by intermittent intravenous administration of anes-
thetic. A large-field gamma camera fitted with a low-energy
and all-purpose collimator allowed visualization of the
whole body of the mouse. For the animal experiment, Na-
tional Institutes of Health (NIH) guidelines for the care and
use of laboratory animals (NIH publication no. 85-23 rev.
1985) were observed.
Biodistribution of surface-modified PLGA
nanospheres
Biodistribution experiments were performed using 4–7-
week-old ICR mice. The mice were injected in the tail vein
with 125I-labeled HPP–Poloxamer 407-coated nanosphere
suspension at 1 Ci of radioactivity. 99mTc-labeled tin
(Stannous) colloid with similar particle size distribution and
radioactivity was used as a control. Mice were sacrificed
after 1, 6, and 24 h. Approximately 0.1-mL blood samples
were collected from the abdominal aorta. Whole blood vol-
ume of the mice was assumed as 0.05 mL/g.27 Subsequently,
liver, spleen, bone, kidneys, heart, lungs, small intestine,
stomach, and muscle were excised. Total radioactivity of
blood and each excised organ was measured using a gamma
counter and presented as the ratio of percent injected dose
(%) to organ weight (g). For this animal experiment, NIH
guidelines for the care and use of laboratory animals (NIH
publication no. 85-23 rev. 1985) were observed.
Statistical analysis
All measurements were collected in triplicate and ex-
pressed as mean  standard deviation. One-way analysis of
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variance was used to measure the statistical significance of
comparing the biodistribution of the 99mTc-tin colloid and
125I-labeled HPP–Poloxamer-coated nanospheres.
RESULTS AND DISCUSSION
Surface modification of ligand-conjugated
Poloxamer 407
Conjugation of HPP to Poloxamer 407 was con-
firmed by examining Fourier transform infrared spec-
tra of ester bonds and differential scanning calorime-
try (new peak attributed to newly formed ester bond)
(data not shown). HPP has a low water solubility;
however, our previous research demonstrated conju-
gated HPP did not significantly affect the hydrophi-
licity of PEO chain, indicating that hydrophobicity of
HPP did not affect the mobility of PEO chain of Polox-
amer 407 while permitting radiolabeling 125I or 131I.28
It should be pointed out that the rationale to include
HPP to the Poloxamer 407 lies in an advantage in
efficient radiolabeling 125I to HPP–Poloxamer 407-
coated nanosphere, while maintaining the steric activ-
ity of the Poloxamer 407 on the nanosphere surface.
The uncoated PLGA nanospheres were found to be
in the 100 nm of mean size range required for long
circulating and following bone/bone marrow imaging
purpose [Fig. 1(a)].20,21 The thickness of the adsorbed
layer on the surface of the nanosphere was expected to
be related to the concentration of Poloxamer 407 and
incubation time. Adsorption of the PEO containing
polymers to the hydrophobic nanospheres has been
reported to increase nanosphere size because of the
formation of a coating layer.29 However, HPP–Polox-
amer 407-coated nanospheres did not show any sig-
nificant difference in size distribution from that of
original uncoated nanospheres (data not shown),
which suggested that coated nanospheres were still
able to be utilized as imaging agents. Because the
adsorbed layers measured in this study were small
compared with the standard deviation of the size mea-
surements, confirmation of nanosphere coating was
obtained by measuring the surface potential of the
nanospheres. The uncoated nanospheres were highly
negatively charged at their surfaces as reflected in
their zeta potentials, being attributed to the presence
of carboxyl groups on the surface of PLGA. In con-
trast, the adsorption of Poloxamer 407 to the nano-
sphere surfaces resulted in decreased surface charge
(increased zeta potential), possibly because of the
masking of the inherent negative charges of the nano-
spheres [Fig. 1(b)]. The PEO chains have been known
to bring about a shift in the shear plane to a distance
further from the nanosphere surface.29 The change of
surface charge could be related to the incubation time
with Poloxamer solution; longer incubation resulted
in less surface charge. However, the surface charge
reached maximum and was maintained for 24 h,
which was attributed to the surface equilibrium of the
adsorption. When HPP–Poloxamer 407 solution was
applied to the nanospheres, surface charge was de-
crease as well; however, there was no significant dif-
ference from that by an adsorption of Poloxamer 407
solution to the nanospheres, indicating that HPP con-
jugation did not alter the surface charge of parent
Poloxamer 407. The zeta potential results are, there-
fore, a confirmation of the presence of a coating layer
on the nanosphere surface. In addition, even after
coating with HPP–Poloxamer 407, the nanospheres
Figure 1. (a) Dynamic light scattering of PLGA nano-
spheres shows unimodal size distribution with a mean di-
ameter of 100 nm. (b) Kinetics of the change in the zeta
potential of the surface of the nanospheres in accordance
with incubation time with the Poloxamer solution; effect of
ligand-conjugated Poloxamer on the surface zeta potential.
Coating with Poloxamer 407 (■), and with HPP–Poloxamer
407 (F).
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possessed the size distribution approximately 100 nm
in average, confirming their potential utility as bone
imaging agents.
Radioisotope labeling and in vitro stability of
HPP–Poloxamer 407-coated nanospheres
Figure 2(a) shows the ITLC/SG chromatogram
demonstrating the labeling efficiency of 125I and 131I to
HPP–Poloxamer-coated nanospheres (10 mg), respec-
tively. HPP–Poloxamer 407-coated nanospheres
showed a labeling efficiency of 90%, as determined by
TLC. Impurities including free isotope were separated
from 125I-HPP–Poloxamer 407-coated nanospheres
and moved up to the 100-mm region with saline, used
as a mobile phase. A single peak of 125I-HPP–Polox-
amer 407-coated nanospheres was observed at the
10-mm point, indicating that added 125I was almost
consumed to label the nanospheres. Figure 2(b) shows
the labeling stability of 125I-, 131I-labeled HPP–Polox-
amer 407-coated nanospheres (5 mg), respectively. Be-
cause half the amount of nanospheres was utilized in
conducting the stability test, overall radioactivity was
smaller than that in Figure 2(a), which might seem to
be decay of radioactivity during incubation. However,
by adjusting the amount of nanospheres, it can be
considered that almost the same radioactivity was
conserved for 24-h incubation, which is coincident to
the general half-life of 125I and 131I. In addition, it
should be pointed out that only a single peak of 125I-,
or 131I-labeled HPP–Poloxamer 407-coated nano-
sphere was observed, with no other peaks related to
dissociated radioisotope. Therefore, radioactive HPP–
Poloxamer 407-coated nanosphere was considered to
be stable in human serum for up to 24 h. High stability
of radioisotope labeling may be due to a stable chela-
tion of the isotope to the ligand which is chemically
linked to the Poloxamer 407. Stable retention of radio-
isotope to carrier colloids under physiological condi-
tion is essential for measuring in vivo distribution of
the colloids. Radioisotopes have been loaded into
polymeric nanoparticulates by physical entrapment or
direct coupling to polymer chains even in the absence
of ligands.24,25,30 Physical entrapment of the radioiso-
topes can incorporate radioisotopes during nano-
sphere preparation. However, radioisotope at the sur-
face of the nanospheres would be lost in a short time
by burst release when injected into the blood stream,
resulting in only a small fraction being retained in the
nanospheres. Thus, those burst and nonspecific leak-
age of the radioisotope from the colloid nanospheres
to the blood stream result in a biodistribution profile
that is not representative of an applied colloid system.
Direct coupling may have an advantage in avoiding
nonspecific isotope leakage to the blood stream; how-
ever, its application is limited because labeling and
purification time may exceed the half-life of the radio-
isotope, which may cause low yield.30 Therefore, the
direct coupling method is inappropriate for a radio-
isotope with a short half-life, such as 99mTc, 131I, and
125I, which are currently used for bone imaging. Poly-
mers synthesized from 14C-radiolabeled monomers
have been used to prepare radiolabeled nanospheres,
for example, 14C-labeled polylactic acid nano-
sphere.31,32 The radiolabel is relatively stable because
14C would be released and excreted only after degra-
dation of polymer. However, its application is quite
limited because it emits -ray, which is not in a suffi-
cient radioactive strength for imaging the target or-
gan. In contrast, our previous and current studies
Figure 2. Labeling efficiency and stability of 125I labeling
(—) or 131I labeling (  ) to nanospheres coated with HPP–
Poloxamer 407. Labeling efficiency was measured by using
ITLC coupled with a radioisotope scanner. Labeled radio-
isotope to the nanospheres was detected below the 40-mm
line whereas free radioisotopes were detected above the
50-mm line. Labeling efficiency (a) and labeling stability (b)
of radioisotope to HPP–Poloxamer 407-coated nanospheres
are shown as chromatograms.
NANOSPHERES FOR TARGETED BONE IMAGING 755
demonstrated that PEO-containing copolymers were
chemically conjugated to the specific ligands before
labeling the desired radioisotope and then radioiso-
topes, such as 99mTc, 125I, and 131I, could chelate spe-
cifically to the ligand on the polymer. Thus, these
ligand-conjugated polymers are ready to carry radio-
isotope to the target, primarily to the bone and bone
marrow. In addition, ITLC data clearly demonstrate
the stable retainment of the radioisotope in the HPP–
Poloxamer 407-coated nanosphere, which enables the
prediction of biodistribution image represented by the
HPP–Poloxamer 407-coated nanospheres. Overall, the
advantage of this system is that it allows easy and
stable chelation of radioisotopes to the ligand-poly-
mers in a short time, which permits prompt use for
organ imaging.
Whole body imaging
Figure 3 shows posterior whole body images of
mouse after administered with 131I-HPP–Poloxamer-
coated nanospheres. For the whole body imaging, 131I
was used because it emits stronger radioactivity for
the imaging. As a control, 99mTc-tin colloid with the
same size distribution was used. The liver/spleen ra-
dioactivity was evident 1 h after injection of 99mTc-tin
colloid [Fig. 3(a)]. 99mTc-antimony, 99mTc-sulfur col-
loid, and 99mTc-tin colloids are currently investigated
imaging agents because they have high sensitivity in
bone imaging. However, those colloids are still re-
quired to have an improvement in targeting efficiency
(currently 0.5–2.7% uptake by the bone, primarily at-
tributed to the surface hydrophobicity). The whole
body image by the 131I-HPP–Poloxamer-coated nano-
spheres was comparable to that of 99mTc-tin colloids
[Fig. 3(b)]. Nanospheres coated with 131I-HPP–Polox-
amer 407 remained largely in the vascular compart-
ment, indicating maintenance in the blood stream, and
demonstrated little uptake in the liver/spleen region
whereas 99mTc-tin colloids were taken up mainly by
liver and spleen. The uptake of the surface-coated
nanospheres in the liver and spleen was largely asso-
ciated with the blood pool in the liver, not with the
liver tissue. It is not surprising that surface-modified
nanoparticulates with PEO showed more retention in
the blood stream while avoiding liver/spleen uptake,
as the previous reports already demonstrated. How-
ever, our system, which permits rapid and stable ra-
diolabeling without any alteration of PEO chain at the
surface, opens possibilities for development of a long
circulating and effective bone-targeting imaging
agent.
Biodistribution of HPP–Poloxamer 407-coated
nanospheres
Figure 4(a) shows the biodistribution of 99mTc-tin
colloids in ICR mouse 1 h after intravenous injection.
After 1 h from injection, most of the injected colloid
was found in the liver, spleen, and lung, compared
with extremely low uptake by the bone (1.2%). This
result is quite coincident to that from whole body
imaging. When 125I-HPP–Poloxamer-coated nano-
spheres were applied to the mouse, the liver and
spleen uptake was notably reduced to 11% and 5%,
respectively [Fig. 4(b)]. In contrast, blood retention
and bone uptake were significantly increased (26%
and 15%, respectively). The high blood retainment
confirms the result from whole body imaging in Fig-
ure 3(b). Compared with that of tin colloid, an increase
in amounts of nanospheres remaining in the blood
induced their migration to the carcass including bone
and bone marrow. The result indicates that these sur-
face-modified nanospheres have proper function of
Figure 3. Whole body scintiscans of mouse 1 h after intra-
venous administration of 99mTc-tin colloid (a) and 131I-HPP–
Poloxamer 407-coated nanospheres (b).
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maintaining blood stability and enhancing bone up-
take whereas avoiding RES uptake.
The levels of HPP–Poloxamer-coated nanospheres
and 99mTc-tin colloids in blood versus time are shown
in Figure 5(a). 99mTc-tin colloids showed lower blood
retention than HPP–Poloxamer-coated nanospheres
for the observation period. Even at 24 h, HPP–Polox-
amer-coated nanospheres showed notably higher re-
tainment in the circulation than 99mTc-tin colloid.
HPP–Poloxamer-coated nanospheres exhibited 17%,
13% of the decrease from the original dose at 6 h and
24 h in the blood, respectively. Thus, prolonged reten-
tion of HPP–Poloxamer-coated nanospheres indicates
that the surface layer of HPP–Poloxamer at the nano-
spheres stably persisted in the blood.
PEO is generally known to suppress protein and
cellular adsorption at the surfaces and interfaces by its
hydrophilicity and chain mobility, and to prolong the
circulation time of the nanoparticles including lipo-
somes.22,23,33–35 It was not surprising that the Polox-
amer-modified nanospheres showed the reduced up-
take by the RES in the liver or spleen, which was
accompanied by extended blood circulation times
[Fig. 5(b,c)]. The ability of PEO-modified drug carriers
in avoiding the RES is in sharp contrast with most
unmodified nanocolloids, which are rapidly cleared
from the circulation within minutes. The Poloxamer-
coated nanospheres clearly demonstrated elevated
plasma levels in accordance with time when com-
pared with 99mTc-tin colloids. Our hypothesis was that
such high retention of particles could result in the
enhanced uptake by bone and bone marrow, which is
another big RES after liver or spleen. The exact mech-
anism of bone and bone marrow uptake remains to be
elucidated; however, our previous and current studies
could propose a responsible mechanism—nano-sized
colloid particles leave the circulation and can be cap-
tured by the liver and spleen. The remaining particles
in the blood stream could enter the extravascular
spaces of the bone and bone marrow with discontinu-
ity of the vascular endothelium and basement mem-
brane.28,36,37 Bone uptake of the HPP–Poloxamer-
coated nanospheres was markedly higher than that of
99mTc-tin colloids up to 24 h, corroborating that these
surface-modified nanospheres had proper function of
enhancing bone uptake while avoiding RES uptake
[Fig. 5 (d)]. The interaction between the surface of the
bone marrow and hydrophilic PEO chain including
Poloxamer has not been clearly established; however,
several hypotheses for the recognition mechanism
have been suggested.36–40 Plasma components, such
as erythropoietin, transferrin, transcobalamine, or en-
dothelial-derived factor, or cellular adhesion molecule
such as lectin, have been proposed to mediate the
recognition of PEO-anchored surface by the bone mar-
row.36–40 When adsorbed onto the surface of Polox-
amer-coated nanospheres, those above recognizable
plasma molecules may exhibit the specificity for cer-
tain microdomains on the bone marrow endothelial
cell surface, which is similar to the uptake of surface-
sugar bearing particles by the hepatocytes in the liver.
Therefore, the nanoparticles with surface PEO by ad-
sorption of Poloxamer can be favorable in improving
blood compatibility by its hydrophilicity, protecting
from RES uptakes, being recognized by the bone mar-
row, hence final enhancement in the bone uptake.
As one of the requirements for an efficient bone
imaging agent, proper excretion may be suggested.14
HPP–Poloxamer-coated nanospheres initially showed
much less uptake by the other organs than liver or
spleen. In addition, the radioactivity significantly re-
duced after 24 h, which provided the evidence of
proper excretion of these nanospheres [Fig. 5(e)]. It
should be pointed out that our system has a unique
Figure 4. Distribution of nanocolloids (presented as per-
cent injected dose/whole organ weight) in mouse tissues
after intravenous administration of 1 Ci of colloids after
1 h; (a) 99mTc-tin colloids, (b) 125I-HPP–Poloxamer-coated
nanospheres. Data are presented as mean  standard devi-
ation (n  6).
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Figure 5. Levels of 99mTc-tin colloids (■) and 125I-HPP–Poloxamer-coated nanospheres (F) in the blood (a), liver (b), spleen
(c), bone (d), and the kidney (e) in accordance with time. Data are presented as mean  standard deviation (n  6). *p  0.05,
as compared with that of 99mTc-tin colloids.
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advantage in labeling radioisotope to the polymeric
colloids via chelation to the ligand which is already
conjugated to the polymeric colloid surface. This
method could offer a rapid and stable radiolabeling to
the colloids whereas maintaining the original behavior
of the colloids in the body. Whole body imaging study
indicates that the use of a more sensitive radioisotope
such as 99mTc, 111In can provide an enhanced imaging.
Overall, the HPP–Poloxamer-coated PLGA nano-
spheres might be suggested as an efficient bone and
bone marrow imaging agent while overcoming the
current limitations in developing bone marrow imag-
ing agents. Optimization of radioisotope labeling to
ligand-polymer, and related bone and bone marrow
uptake research is now in progress in our laboratory.
CONCLUSION
Radioisotope carrying, surface-modified PLGA
nanospheres were prepared for targetable bone and
bone marrow imaging. The nanospheres were coated
by ligand-conjugated Poloxamer 407 to provide the
nanospheres with the surface hydrophilicity due to
PEO segment and ease of radiolabeling. These nano-
spheres had proper size distribution and hydrophilic-
ity for effective bone imaging. The ligand-conjugated
Poloxamer 407-coated nanospheres showed higher
and stable radioisotope labeling efficiency. In addi-
tion, radioisotope-carrying nanospheres demon-
strated increased blood circulation followed by bone
uptake. Therefore, the Poloxamer 407-coated nano-
spheres, which carryies radioisotope might be a
potential tool for effective bone and bone marrow
imaging.
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